Showing 91 - 100 of 261
This paper analyses the widespread difference in COVID-19 vaccination and Non-Pharmaceutical interventions (NPI) acceptance by the European population and finds that this difference can be clustered in nine archetype clusters. Calibrating a SIR model with control acceptance on COVID-19...
Persistent link: https://www.econbiz.de/10013241468
We estimate a reduced form of employment at the COVID time through a simple labor market equilibrium that accounts for workers possibly fearing work on-site (FOG) and for firms’ strategies such as work from home (WFH). Employment estimates on the French market demonstrate that work allocation...
Persistent link: https://www.econbiz.de/10013241541
Despite promising announcements on an effective vaccine, the control of the COVID-19 pandemic is critically dependent on the maximal compliance of citizens to a set of non-pharmaceutical interventions (NPI for short). We use statistical clustering to partition European citizens with regards to...
Persistent link: https://www.econbiz.de/10013252190
Persistent link: https://www.econbiz.de/10013285579
Many firms actively disclose research findings in scientific peer-reviewed journals. The literature highlights several potential benefits of such scientific boundary-spanning activities, including privileged access to academic information networks. However, scientific disclosure may lead to...
Persistent link: https://www.econbiz.de/10013035156
This paper examines the sources of Europe's lagging business R&D performance relative to the US, particularly the role played by missing young leading innovators in high technology intensive sectors in Europe. It investigates through econometric analysis differences in the rates of return to R&D...
Persistent link: https://www.econbiz.de/10013060462
Persistent link: https://www.econbiz.de/10012418541
Persistent link: https://www.econbiz.de/10012418570
Persistent link: https://www.econbiz.de/10012242880
Based on an original data set with information of a representative portfolio of among the largest 304 Research and Development (R&D) investing companies over the 20032006 period, the overall analysis, except in a few cases, gives some robust evidence of a positive relationship between top...
Persistent link: https://www.econbiz.de/10012056178